TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34471639

Group type: EXPERIMENTAL
Intervention: Single PED without coils
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oversized PED placed from M1 to the ICA
Number of subjects: 48
Study: 34471928

Group type: EXPERIMENTAL
Intervention: Daily physical activity
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Low activity group
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Mid activity group
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: High activity group
Number of subjects: 1410
Study: 34472021

Group type: EXPERIMENTAL
Intervention: CHAMP intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 151
Study: 34472035

Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 135

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 135
Study: 34472719

Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy (ABC)
Number of subjects: 3393
Study: 34472769

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program combined with oral antioxidant therapy (multivitamins, coenzyme Q10, omega-3, and oligo-elements) for 3 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (10 healthy male volunteers)
Number of subjects: 93
Study: 34472988

Group type: EXPERIMENTAL
Intervention: AVAS classification
Number of subjects: 140
Study: 34473061

Group type: EXPERIMENTAL
Intervention: Serious health computer game promoting a healthy lifestyle
Number of subjects: 157

Group type: COMPARATOR
Intervention: Regular classes (control)
Number of subjects: 157
Study: 34473227

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) methods for classification of olfactory dysfunction
Number of subjects: 611

Group type: COMPARATOR
Intervention: Traditional logistic regression for classification of olfactory dysfunction
Number of subjects: 611
Study: 34473237

Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VSTs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Third-party VSTs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Donor-derived VSTs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VSTs from both donor sources
Number of subjects: 30
Study: 34473258

Group type: EXPERIMENTAL
Intervention: Educational outreach and audit and feedback strategies
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Educational outreach
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 847
Study: 34473343

Group type: COMPARATOR
Intervention: Bamlanivimab (0.7 g)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Bamlanivimab (2.8 g)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Bamlanivimab (7.0 g)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Bamlanivimab/etesevimab
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Casirivimab/imdevimab (2.4 g)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Casirivimab/imdevimab (8.0 g)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Sotrovimab
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Regdanvimab (40 mg/kg)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Regdanvimab (80 mg/kg)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Bamlanivimab (hospitalised)
Number of subjects: 17495

Group type: COMPARATOR
Intervention: Casirivimab/imdevimab (hospitalised)
Number of subjects: 17495
Study: 34473588

Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs) and caregivers' perceptions of nutritional status
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Gross Motor Function Classification System (GMFCS) levels
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Concerns about nutritional status
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Agreement between HCP and caregiver perceptions
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Objective nutritional status assessment
Number of subjects: 497
Study: 34473594

Group type: EXPERIMENTAL
Intervention: VARIVAX™ (Varicella Virus Vaccine Live [Oka/Merck]) 0.5 mL, 2 doses 6 weeks apart
Number of subjects: 50
Study: 34473740

Group type: EXPERIMENTAL
Intervention: Gadolinium-chelate (Gd) enhanced dynamic MRI
Number of subjects: 134
Study: 34473939

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34474014

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on organ transplantation rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplant rate patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal trends in transplant activity
Number of subjects: 0
Study: 34474164

Group type: EXPERIMENTAL
Intervention: Pembrolizumab prior to alloSCT
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no prior ICI exposure)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pembrolizumab prior to alloSCT with post-transplantation cyclophosphamide (PTCy)
Number of subjects: 9
Study: 34474584

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloons (DEB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thin-Strut Drug-Eluting Stents (DES)
Number of subjects: 0
Study: 34474597

Group type: EXPERIMENTAL
Intervention: Coronary microcirculatory dysfunction assessed by index of microcirculatory resistance (IMR)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Surveillance endomyocardial biopsy
Number of subjects: 154
Study: 34474640

Group type: EXPERIMENTAL
Intervention: Venetoclax and decitabine
Number of subjects: 0
Study: 34474927

Group type: EXPERIMENTAL
Intervention: AVB-500 + PAC
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: AVB-500 + PAC (subgroup with no prior bevacizumab or AVB-500 trough levels >13.8 mg/L)
Number of subjects: 53

Group type: COMPARATOR
Intervention: AVB-500 + PLD
Number of subjects: 53
Study: 34474932

Group type: EXPERIMENTAL
Intervention: Camera-based prototype application (CBPA) measuring pulse rate (PR)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Pulse oximetry (reference method)
Number of subjects: 446
Study: 34475142

Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi)
Number of subjects: 200
Study: 34475166

Group type: EXPERIMENTAL
Intervention: Vaginal palpation of pelvic floor muscle function assessment
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Assessment of involuntary contraction and voluntary relaxation
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Calliper measurement of diastasis recti abdominis width at umbilicus after 2 months of training
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Assessment of diastasis recti abdominis depth and bulging
Number of subjects: 222
Study: 34475172

Group type: EXPERIMENTAL
Intervention: Trust network
Number of subjects: 2890

Group type: EXPERIMENTAL
Intervention: Multiplex network (trust and health advice)
Number of subjects: 2890

Group type: COMPARATOR
Intervention: Health advice-only network
Number of subjects: 2890

Group type: COMPARATOR
Intervention: Trust-only network
Number of subjects: 2890

Group type: EXPERIMENTAL
Intervention: Overall CVD risk score (QRISK3)
Number of subjects: 2890
Study: 34475174

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact
Number of subjects: 667
Study: 34475253

Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System (Y-stenting technique)
Number of subjects: 106
Study: 34475366

Group type: EXPERIMENTAL
Intervention: Bladder Stimulation Technique (BST)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Urethral Catheterization
Number of subjects: 124
Study: 34475750

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) intravitreal implant 700 µg
Number of subjects: 700
Study: 34475849

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34476122

Group type: EXPERIMENTAL
Intervention: Acute medication overuse (AMO)
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Simple analgesics, combination analgesics, and opioids
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Factors associated with AMO
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: AMO respondents
Number of subjects: 16789

Group type: COMPARATOR
Intervention: AMO vs non-AMO migraine respondents
Number of subjects: 16789
Study: 34476128

Group type: EXPERIMENTAL
Intervention: Edaravone for 24 weeks (6 cycles)
Number of subjects: 200
Study: 34476229

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) intervention, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 34476329

Group type: EXPERIMENTAL
Intervention: PCR-based comprehensive genomic profiling (PCR-CGP) test
Number of subjects: 32048

Group type: EXPERIMENTAL
Intervention: PCR-CGP attempted
Number of subjects: 32048
Study: 34476411

Group type: EXPERIMENTAL
Intervention: Combination of effusion and haemarthrosis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Synovial fluid molecular protein response (MCP-1 and IL-6)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clinical predictors (baseline demographic and clinical factors)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 150
Study: 34476468

Group type: EXPERIMENTAL
Intervention: Omics model based on magnitude and timing of postprandial biomarkers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Simpler model based on postprandial BP and age
Number of subjects: 100

Group type: COMPARATOR
Intervention: Baseline clinical parameters or fasting biomarkers
Number of subjects: 100
Study: 34476587

Group type: EXPERIMENTAL
Intervention: Dry electrode electroencephalography (EEG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined weighted phase lag index and relative theta power
Number of subjects: 100
Study: 34476621

Group type: EXPERIMENTAL
Intervention: Progranulin
Number of subjects: 541
Study: 34476623

Group type: EXPERIMENTAL
Intervention: Therapist-report measure of family therapy techniques (ITT-CEFT)
Number of subjects: 68
Study: 34476665

Group type: EXPERIMENTAL
Intervention: Aortic stiffness measured by aortic pulse wave velocity (PWV)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Age and hypertension as predictors of aortic stiffness
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: High aortic stiffness (PWV)
Number of subjects: 408
Study: 34476728

Group type: EXPERIMENTAL
Intervention: Polysomnography performed within 7 days of stroke onset (n=91) and after 6 months (n=52)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Persistent SDB (AHI ≥ 15 in both acute state and follow-up)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: AHI measurement
Number of subjects: 99
Study: 34476771

Group type: EXPERIMENTAL
Intervention: ECL assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial ELISA kits (GenWay BioTech and Demeditec Diagnostics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial ELISA kits
Number of subjects: 0
Study: 34477016

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 324
Study: 34477094

Group type: EXPERIMENTAL
Intervention: Ambulance dispatched with lights and sirens
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Dispatch criterion: sudden severe headache
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Time from emergency call to neurosurgical admission
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Patients brought directly to a hospital with neurosurgical facilities
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Overall dispatch criteria effectiveness
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Patients not initially brought to a hospital with neurosurgical facilities
Number of subjects: 262
Study: 34477118

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 320
Study: 34477845

Group type: EXPERIMENTAL
Intervention: Preconception leukocyte telomere length (measured as a ratio T/S using PCR)
Number of subjects: 1228
Study: 34477937

Group type: EXPERIMENTAL
Intervention: fedratinib 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: cocktail of digoxin 0.25 mg, rosuvastatin 10 mg, and metformin 1000 mg
Number of subjects: 24
Study: 34477993

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (adalimumab, etanercept)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 120
Study: 34477998

Group type: EXPERIMENTAL
Intervention: IgA deficiency (n=35)
Number of subjects: 659

Group type: COMPARATOR
Intervention: A-T patients without IgA deficiency (n=31)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Overall survival of patients with IgA deficiency
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: IgA as a surrogate marker
Number of subjects: 659
Study: 34478115

Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation
Number of subjects: 42
Study: 34478460

Group type: EXPERIMENTAL
Intervention: Live attenuated cholera vaccine
Number of subjects: 12
Study: 34478486

Group type: EXPERIMENTAL
Intervention: Akkermansia expansion in the gut
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gut microbial-derived indole compounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum metabolome signatures
Number of subjects: 0
Study: 34478487

Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional chemotherapy (SCHOLAR-1)
Number of subjects: 101
Study: 34478498

Group type: EXPERIMENTAL
Intervention: Cold-stored platelets (CSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room temperature-stored platelets (RSP)
Number of subjects: 0
Study: 34478737

Group type: EXPERIMENTAL
Intervention: Digital single-operator cholangioscopy (DSOC) using the Mendoza Classification
Number of subjects: 14
Study: 34478825

Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding (TRF) - 4-6 hours eating window, 18-20 hours fasting window daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding (TRF)
Number of subjects: 32
Study: 34479230

Group type: EXPERIMENTAL
Intervention: High-definition transcranial burst electrostimulation device
Number of subjects: 0
Study: 34479362

Group type: EXPERIMENTAL
Intervention: 75-g glucose drink (OG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: liquid mixed meal (LMM)
Number of subjects: 10
Study: 34479517

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (low carbohydrate diet)
Number of subjects: 57
Study: 34479526

Group type: EXPERIMENTAL
Intervention: Face-it intervention (health promotion intervention including a health pedagogic dialogue tool and a digital health app)
Number of subjects: 0
Study: 34479581

Group type: EXPERIMENTAL
Intervention: Single-fraction SBRT (15-20 Gray)
Number of subjects: 40
Study: 34479649

Group type: EXPERIMENTAL
Intervention: Arts-only intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mindfulness-only intervention
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mindfulness-based art intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 120
Study: 34479654

Group type: EXPERIMENTAL
Intervention: Reflective writing by facilitators after each facilitation call
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Reflective writing process
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Use of reflective writing
Number of subjects: 2
Study: 34479739

Group type: EXPERIMENTAL
Intervention: Stem cell therapy
Number of subjects: 267

Group type: COMPARATOR
Intervention: Cone reconstruction (CR)
Number of subjects: 267
Study: 34479925

Group type: EXPERIMENTAL
Intervention: MVA-BN-brachyury-TRICOM vaccine administered intravenously at three dose levels on days 1, 22, and 43.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MVA-BN-brachyury-TRICOM vaccine
Number of subjects: 13
Study: 34480095

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 42
Study: 34480329

Group type: EXPERIMENTAL
Intervention: High contact perpetrators
Number of subjects: 4554

Group type: EXPERIMENTAL
Intervention: Low contact perpetrators
Number of subjects: 4554

Group type: EXPERIMENTAL
Intervention: Sexual harassment perpetrators
Number of subjects: 4554

Group type: COMPARATOR
Intervention: Non-perpetrators
Number of subjects: 4554
Study: 34480368

Group type: EXPERIMENTAL
Intervention: Vaccination with carcinoembryonic antigen (CEA) and Her2/neu (Her2) peptides
Number of subjects: 0
Study: 34480474

Group type: EXPERIMENTAL
Intervention: YuWell YE900 oscillometric blood pressure monitor
Number of subjects: 85
Study: 34481135

Group type: EXPERIMENTAL
Intervention: Surgical procedure with added steps to conventional MIS radical hysterectomy
Number of subjects: 0
Study: 34481605

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34482181

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 37
Study: 34482353

Group type: EXPERIMENTAL
Intervention: Latency reversal agents (LRA) - HDAC inhibitor
Number of subjects: 13
Study: 34482507

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) in sub-acute phase (-11.8 ± 3.0%)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) in chronic phase (-14.3 ± 2.9%)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Improvement of GLS from sub-acute to chronic phase
Number of subjects: 77
Study: 34482636

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 0
Study: 34482652

Group type: EXPERIMENTAL
Intervention: Quality of life perceptions among frail older persons
Number of subjects: 78
Study: 34482715

Group type: EXPERIMENTAL
Intervention: Baseline risk factors (alanine transaminase)
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Baseline risk factors (systolic blood pressure)
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Baseline risk factors (arterial hypertension)
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Baseline risk factors (non-high-density lipoprotein cholesterol)
Number of subjects: 956

Group type: EXPERIMENTAL
Intervention: Baseline risk factors (low-density lipoprotein cholesterol)
Number of subjects: 956
Study: 34483038

Group type: EXPERIMENTAL
Intervention: C3-targeted drug candidate
Number of subjects: 0
Study: 34483270

Group type: EXPERIMENTAL
Intervention: Topical insulin (1 unit per mL), applied 4 times per day until resolution of persistent epithelial defect (PED) or ulcer.
Number of subjects: 21
Study: 34484101

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A treatment, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34484187

Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine
Number of subjects: 7
Study: 34484431

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg orally each day continuously until unacceptable toxicity or tumor progression
Number of subjects: 22
Study: 34484473

Group type: EXPERIMENTAL
Intervention: Durvalumab after concurrent chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo after concurrent chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab with subsequent immunotherapy removed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with subsequent immunotherapy removed
Number of subjects: 0
Study: 34484887

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait list/treatment as usual (WL/TAU)
Number of subjects: 60
Study: 34484928

Group type: EXPERIMENTAL
Intervention: eFIT (online moderated structured groups)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: eJournal (online independent journaling)
Number of subjects: 37

Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 37
Study: 34485200

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34485235

Group type: EXPERIMENTAL
Intervention: Healthcare Non-Take-Up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34485595

Group type: EXPERIMENTAL
Intervention: filgrastim and plerixafor
Number of subjects: 11
Study: 34485882

Group type: EXPERIMENTAL
Intervention: Locoregional therapies (LRT) before liver transplantation (LT)
Number of subjects: 2441

Group type: COMPARATOR
Intervention: All-comers group
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: UCSF-DS group
Number of subjects: 2441
Study: 34486544

Group type: EXPERIMENTAL
Intervention: BChE-deficient neuroblastoma cells (KO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild-type neuroblastoma cells (WT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KO xenografts in female mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: WT xenografts in female mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KO and WT tumors
Number of subjects: 0
Study: 34487039

Group type: EXPERIMENTAL
Intervention: MELD-XI score = 12
Number of subjects: 2993

Group type: COMPARATOR
Intervention: MELD-XI score < 12
Number of subjects: 2993
Study: 34487174

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 4104
Study: 34487283

Group type: EXPERIMENTAL
Intervention: Optimal administered radioactivity
Number of subjects: 0
Study: 34487786

Group type: EXPERIMENTAL
Intervention: Culprit lesion optical coherence tomography (OCT) imaging
Number of subjects: 100
Study: 34487890

Group type: EXPERIMENTAL
Intervention: Robot-assisted uterus retrieval
Number of subjects: 1
Study: 34488636

Group type: EXPERIMENTAL
Intervention: Caring Partner
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Worried Manager
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Desperate Overburdened
Number of subjects: 9
Study: 34488662

Group type: EXPERIMENTAL
Intervention: Selinexor with low dose dexamethasone
Number of subjects: 80
Study: 34488832

Group type: EXPERIMENTAL
Intervention: APOE4 allele presence
Number of subjects: 0
Study: 34488884

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 9
Study: 34489264

Group type: EXPERIMENTAL
Intervention: Perioperative care management for diabetic patients
Number of subjects: 5000
Study: 34489289

Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding for at least 3 months
Number of subjects: 350